Skip to content

Evaluation of Adjuvant Therapy Efficacy in Differentiated Thyroid Carcinoma: A Comparative Study of 100mCi versus 150mCi ¹³¹I Treatment Regimens

Evaluation of Adjuvant Therapy Efficacy in Differentiated Thyroid Carcinoma: A Comparative Study of 100mCi versus 150mCi ¹³¹I Treatment Regimens

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098006
Enrollment
Unknown
Registered
2025-02-28
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Observation group:None

Sponsors

Cancer Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with differentiated thyroid cancer and has completed total thyroidectomy; 2. Postoperative imaging examination showed the presence of residual disease, or abnormal postoperative thyroglobulin level (>10 ng/mL); 3. Age between 18 and 75 years old, gender is not limited; 4. Meet the requirements of a low-iodine diet and further ¹³¹I treatment preparation.

Exclusion criteria

Exclusion criteria: 1. Incomplete operation and too much residual thyroid tissue; 2. Ultrasound showed suspicious residual lymph node metastasis in the neck (length diameter >1cm); 3. Diagnostic active iodine-131 scintigraphy and/or therapeutic active iodine-131 scintigraphy showing cervical lymph node remnant (length diameter >1cm) and/or distant metastasis; 4. Patients have received radiotherapy or chemotherapy within 6 months prior to enrollment; 5. Presence of concomitant major medical diseases (such as severe heart disease, liver and kidney insufficiency, etc.).

Design outcomes

Primary

MeasureTime frame
Thyroglobulin;Anti-thyroglobulin antibody;

Secondary

MeasureTime frame
131I Dx-WBS;Neck ultrasound ;

Countries

China

Contacts

Public ContactWen Huling

Cancer Hospital of Shantou University Medical College

wenhuling@163.com+86 139 2396 9236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026